Expression, purification, and initial characterization of different domains of recombinant mouse 2′,3′-cyclic nucleotide 3′- phosphodiesterase, an enigmatic enzyme from the myelin sheath

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Myllykoski, Matti ^a   Kursula, Petri ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI; TOBACCO ETCH VIRUS; VERTEBRATA;

EID: 77954640196     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-12     Document Type: Article

References (30)

1. Structural properties of proteins specific to the myelin sheath. P Kursula, Amino Acids 2008 34 175 185 10.1007/s00726-006-0479-7 17177074
2. Cellular and subcellular distribution of 2′,3′-cyclic nucleotide 3′-phosphodiesterase and its mRNA in the rat central nervous system. BD Trapp L Bernier SB Andrews DR Colman, J Neurochem 1988 51 859 868 10.1111/j.1471-4159.1988.tb01822.x 2842456
3. Isoprenoid modification permits 2′,3′-cyclic nucleotide 3′-phosphodiesterase to bind to membranes. PE Braun D De Angelis WW Shtybel L Bernier, J Neurosci Res 1991 30 540 544 10.1002/jnr.490300311 1666129
4. Binding of 2′,3′-cyclic nucleotide 3′-phosphodiesterase to myelin: an in vitro study. DA De Angelis PE Braun, J Neurochem 1996 66 2523 2531 8632178
5. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. C Lappe-Siefke S Goebbels M Gravel E Nicksch J Lee PE Braun IR Griffiths KA Nave, Nat Genet 2003 33 366 374 10.1038/ng1095 12590258
6. CNP is required for maintenance of axon-glia interactions at nodes of Ranvier in the CNS. MN Rasband J Tayler Y Kaga Y Yang C Lappe-Siefke KA Nave R Bansal, Glia 2005 50 86 90 10.1002/glia.20165 15657937
7. Early ultrastructural defects of axons and axon-glia junctions in mice lacking expression of Cnp1. JM Edgar M McLaughlin HB Werner MC McCulloch JA Barrie A Brown AB Faichney N Snaidero KA Nave IR Griffiths, Glia 2009 57 1815 1824 10.1002/glia.20893 19459211
8. Axon-myelin interactions during a viral infection of the central nervous system. M Brahic JP Roussarie, PLoS Pathog 2009 5 1000519 10.1371/journal.ppat. 1000519 19779566
9. T cell response to 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in multiple sclerosis patients. PA Muraro M Kalbus G Afshar HF McFarland R Martin, J Neuroimmunol 2002 130 233 242 10.1016/S0165-5728(02)00229-1 12225906
10. Dual implication of 2′,3′-cyclic nucleotide 3′ phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. MJ Walsh JM Murray, J Clin Invest 1998 101 1923 1931 10.1172/JCI1983 9576757
11. Transketolase and 2′,3′-cyclic-nucleotide 3′-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. L Lovato R Cianti B Gini S Marconi L Bianchi A Armini E Anghileri F Locatelli F Paoletti D Franciotta L Bini B Bonetti, Mol Cell Proteomics 2008 7 2337 2349 10.1074/mcp.M700277-MCP200 18676363
12. Hydrolysis of ribonucleoside 2′,3′-cyclic phosphates by a diesterase from brain. GI Drummond NT Iyer J Keith, J Biol Chem 1962 237 3535 3539
13. 2′,3′-cyclic nucleotide 3′-phosphodiesterase: Molecular characterization and possible functional significance. Y Tsukada T Kurihara, Myelin: biology and chemistry Boca Raton, FL: CRC Press, Martenson RE, 1992 449 480
14. Mammalian 2′,3′ cyclic nucleotide phosphodiesterase (CNP) can function as a tRNA splicing enzyme in vivo. B Schwer A Aronova A Ramirez P Braun S Shuman, RNA 2008 14 204 210 10.1261/rna.858108 18094118
15. 2′,3′-Cyclic nucleotide 3′-phosphodiesterase: a novel RNA-binding protein that inhibits protein synthesis. M Gravel F Robert V Kottis IE Gallouzi J Pelletier PE Braun, J Neurosci Res 2009 87 1069 1079 10.1002/jnr.21939 19021295
16. Mitochondrial localization of CNP2 is regulated by phosphorylation of the N-terminal targeting signal by PKC: implications of a mitochondrial function for CNP2 in glial and non-glial cells. J Lee RC O'Neill MW Park M Gravel PE Braun, Mol Cell Neurosci 2006 31 446 462 10.1016/j.mcn.2005.10.017 16343930
17. Identification of essential residues in 2′,3′-cyclic nucleotide 3′-phosphodiesterase. Chemical modification and site-directed mutagenesis to investigate the role of cysteine and histidine residues in enzymatic activity. J Lee M Gravel E Gao RC O'Neill PE Braun, J Biol Chem 2001 276 14804 14813 10.1074/jbc.M009434200 11278504
18. Three-dimensional structure of a cyclic-nucleotide phosphodiesterase from human brain. Y Sakamoto N Tanaka T Ichimiya T Kurihara KT Nakamura, Nucleic Acids Symp Ser (Oxf) 2004 157 158 10.1093/nass/48.1.157 17150526
19. Structural evidence that brain cyclic nucleotide phosphodiesterase is a member of the 2H phosphodiesterase superfamily. G Kozlov J Lee D Elias M Gravel P Gutierrez I Ekiel PE Braun K Gehring, J Biol Chem 2003 278 46021 46028 10.1074/jbc.M305176200 12947117
20. Molecular cloning and characterization of rat brain 2′,3′- cyclic nucleotide 3′-phosphodiesterase isoform 2. M Gravel D DeAngelis PE Braun, J Neurosci Res 1994 38 243 247 10.1002/jnr.490380302 7932861
21. The N-terminal domain of 2′,3′-cyclic nucleotide 3′-phosphodiesterase harbors a GTP/ATP binding site. S Stingo M Masullo E Polverini C Laezza I Ruggiero R Arcone E Ruozi F Dal Piaz AM Malfitano AM D'Ursi M Bifulco, Chem Biol Drug Des 2007 70 502 510 10.1111/j.1747-0285.2007.00592.x 17986204
22. The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. S Graslund J Sagemark H Berglund LG Dahlgren A Flores M Hammarstrom I Johansson T Kotenyova M Nilsson P Nordlund J Weigelt, Protein Expr Purif 2008 58 210 221 10.1016/j.pep.2007.11.008 18171622
23. Encephalitogenicity of myelin-associated oligodendrocytic basic protein and 2′,3′-cyclic nucleotide 3′-phosphodiesterase for BALB/c and SJL mice. JA Maatta MS Kaldman S Sakoda AA Salmi AE Hinkkanen, Immunology 1998 95 383 388 10.1046/j.1365-2567.1998.00605.x 9824501
24. Effect of N-terminal solubility enhancing fusion proteins on yield of purified target protein. M Hammarstrom EA Woestenenk N Hellgren T Hard H Berglund, J Struct Funct Genomics 2006 7 1 14 10.1007/s10969-005-9003-7 16850178
25. Improved solubility of TEV protease by directed evolution. S van den Berg PA Lofdahl T Hard H Berglund, J Biotechnol 2006 121 291 298 10.1016/j.jbiotec.2005.08.006 16150509
26. Protein production by auto-induction in high density shaking cultures. FW Studier, Protein Expr Purif 2005 41 207 234 10.1016/j.pep.2005.01.016 15915565
27. Thermofluor-based high-throughput stability optimization of proteins for structural studies. UB Ericsson BM Hallberg GT Detitta N Dekker P Nordlund, Anal Biochem 2006 357 289 298 10.1016/j.ab.2006.07.027 16962548
28. 2′,3′-Cyclic NADP as a substrate for 2′,3′-cyclic nucleotide 3′-phosphohydrolase. DC Sogin, J Neurochem 1976 27 1333 1337 10.1111/j.1471-4159.1976.tb02612.x 12248
29. CDtool-an integrated software package for circular dichroism spectroscopic data processing, analysis, and archiving. JG Lees BR Smith F Wien AJ Miles BA Wallace, Anal Biochem 2004 332 285 289 10.1016/j.ab.2004.06.002 15325297
30. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. L Whitmore BA Wallace, Nucleic Acids Res 2004 32 668 73 10.1093/nar/gkh371 15215473